NEW YORK (Reuters Health)—In Lyme-endemic areas, synovial fluid white blood cell (WBC) count isn’t very helpful in distinguishing septic from Lyme arthritis of the hip, a new study suggests. Use of newer-generation Lyme disease diagnostics are necessary to avoid the “under- and overdiagnosis of Lyme arthritis at the time that initial management decisions must be…
Articles by Natasha Yetman
FDA Staff Raises Safety Concerns Over Arthritis Drug Baricitinib
(Reuters)—An experimental rheumatoid arthritis drug developed by Eli Lilly and Co. and Incyte Corp. poses serious risks of deadly blood clots at higher doses, U.S. Food and Drug Administration staff says, the latest setback to a treatment regulators declined to approve last year. New data provided by the companies in a resubmission of their marketing…
Denosumab May Work Better Than Risedronate for Steroid-Induced Osteoporosis
NEW YORK (Reuters Health)—The RANKL inhibitor denosumab is superior to the bisphosphonate risedronate in increasing bone-mineral density (BMD) at the lumbar spine in patients just starting or continuing steroid therapy, according to 12-month results of a 24-month randomized controlled study. “Glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis and increases the risk of…
Poor Sleep Quality During Menopause Tied to Increased Inflammation
(Reuters Health)—Middle-aged women who get poor quality sleep have elevated levels of inflammatory markers, suggesting their risk for heart disease and other illnesses may be increased, U.S. researchers say. Based on sleep monitoring and blood tests of 295 women, most of whom were past menopause, researchers found those who had trouble falling asleep or who…
AbbVie, Samsung Bioepis in Deal; Humira Biosimilar U.S. Release in 2023
(Reuters)—AbbVie Inc. on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc. that would fend off U.S. competition of their biosimilar version to blockbuster drug, adalimumab (Humira), until 2023. This is the second deal AbbVie has signed over the past year as it tries to safeguard patents on Humira,…
Supply & Demand: Where Will the Rheumatology Workforce Be in 2030?
According to the “2015 American College of Rheumatology Workforce Study: Supply and Demand Projections of Adult Rheumatology Workforce, 2015–2030,” the demand for rheumatologic care is projected to exceed supply of clinical adult rheumatology providers by 4,133 clinical FTEs by 2030. The research now being published estimates the baseline adult rheumatology workforce, as well as determined demographic and geographic factors relevant to the workforce. The research also highlights the need for innovative regional strategies to manage future access to and reduce barriers to care for rheumatology patients in underserved regions…
Tai Chi at Least as Good as Aerobic Exercise for Fibromyalgia
NEW YORK (Reuters Health)—Tai chi improves fibromyalgia symptoms at least as effectively as aerobic exercise, according to a new trial. Aerobic exercise is the most commonly recommended non-drug treatment for fibromyalgia, Dr. Chenchen Wang of Tufts University School of Medicine in Boston and her colleagues note in The BMJ, online March 12.1 However, Dr. Wang…
Chikungunya Arthritis
In this review, the authors address the key pathophysiologic mechanisms that drive acute and chronic chikungunya arthritis, arguably the most incapacitating sequela among long-lasting chikungunya virus disease manifestations, based on recent animal experimental disease models and epidemiologic studies. They explore the latest findings in therapeutic development aimed at limiting viral spread and at immune and…
Baricitinib Appears Effective in Biologic-Refractory RA
NEW YORK (Reuters Health)—The selective Janus kinase 1 and 2 inhibitor baricitinib appears also to help patients whose rheumatoid arthritis (RA) has not responded adequately to biologic disease-modifying antirheumatic drugs, according to results from the RA-BEACON randomized trial. The previously published overall results from RA-BEACON showed that baricitinib-treated patients had significantly better functional and clinical…
U.S. Health Spending Is Twice Other Countries’, with Worse Results
(Reuters Health)—The U.S. spends about twice what other high-income nations do on healthcare, but has the lowest life expectancy and the highest infant mortality rates, a new study suggests. More doctor visits and hospital stays aren’t the problem. Americans use roughly the same amount of health services as people in other affluent nations, the study…
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- …
- 97
- Next Page »